Hot Topics

A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath
Gillian Woollett, MA, DPhil , Bruce Pyenson, FSA, MAAA
Web Exclusives - Hot Topics

Current Issue

Is Adequate Nutrition Cost-Effective?
David B. Nash, MD, MBA
May 2018 Vol 11, No 3 - Editorial
Read More
Comparing Treatment Modalities for End-Stage Renal Disease: A Meta-Analysis
Gilbert L. Queeley, PhD, Ellen S. Campbell, PhD
May 2018 Vol 11, No 3 - Clinical, Original Research
Stakeholder Perspective
Dialysis Procedures and Health-Related Quality of Life: The Challenge of Creating Evidence-Based Healthcare in End-Stage Renal Disease
by Michael F. Murphy, MD, PhD
Read More
Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States
Kathleen F. Villa, MS, Nancy L. Reaven, MA, Susan E. Funk, MBA, Karen McGaughey, PhD, Jed Black, MD
May 2018 Vol 11, No 3 - Business, Original Research
Stakeholder Perspective
Accurate Diagnosis of Chronic Diseases Can Reduce Costs and Medical Resource Utilization
by James T. Kenney, RPh, MBA
Read More
Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry
Dimitrios A. Pappas, MD, Robert A. Gerber, PharmD, Heather J. Litman, PhD;, David Gruben, PhD, Jamie Geier, PhD, Winnie D. Hua, MS, Connie Chen, PharmD, Youfu Li, MD, MPH, Joel M. Kremer, MD, John S. Andrews, MD, Jeffrey A. Bourret, PharmD
May 2018 Vol 11, No 3 - Clinical, Original Research
Stakeholder Perspective
Limited Guidelines and Treatment Success in the Current Standard of Care for Patients with Rheumatoid Arthritis Provide an Opportunity to Inform New Treatment Protocols
by Gary Branning, MBA
Read More

Conference Correspondent

Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent - ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Conference Correspondent - ACR 2017, Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Conference Correspondent - ACR 2017, Conference Correspondent
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
Conference Correspondent - ACR 2017, Conference Correspondent

Most Popular Articles

A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath
Gillian Woollett, MA, DPhil , Bruce Pyenson, FSA, MAAA
Web Exclusives - Hot Topics
Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study
Todd Williamson, PhD, MSc, Wendy Y. Cheng, MPhil, MPH, Nora McCormick, MSc, Francis Vekeman, MA
April 2018 Vol 11, No 2 - Clinical, Original Research
Effects of Educational Messaging on Urgent and Emergent Care–Seeking Behaviors Among Publicly Insured Populations
Jesse Cambon, MEng, Tristan Cordier, MS, Elizabeth L. Munnich, PhD, MPP, Andrew Renda, MD, Bobby Kapur, MD, MPH, Shkelzen Hoxhaj, MD, MPH, MBA, Meredith Williams, MD, MBA
April 2018 Vol 11, No 2 - Business, Original Research
FDA Approvals of Brand-Name Prescription Drugs in 2017
March 2018, Vol 11, Ninth Annual Payers' Guide - FDA Approvals, News & Updates
Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System
Raghu Durvasula, MD, MHA, Janet Kelly, PharmD, Anneliese Schleyer, MD, MHA, Bradley D. Anawalt, MD, Shabir Somani, MS, MBA, RPh, FASHP, Timothy H. Dellit, MD
April 2018 Vol 11, No 2 - Business

Web Exclusives

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer
HER2-positive breast cancers are aggressive tumors and can spread to other parts of the body, making adjuvant therapy an important part of the treatment plan.
Read More

Select Drug Updates

Yondelis (Trabectedin) Approved for the Treatment of Unresectable or Metastatic Soft-Tissue Sarcomas
Vyvanse (Lisdexamfetamine Dimesylate): First FDA-Approved Drug for the Treatment of Adults with Binge-Eating Disorder
Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
Tagrisso (Osimertinib) Approved for Patients with Non–Small-Cell Lung Cancer and the EGFR T790M Mutation
View All Updates

Reader Poll

*Should the government fund healthcare cost-sharing payments to insurers to reduce the economic burden on consumers?


  • Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME